Ozempic Alternatives UK: What Are Your Options in 2026?

Ozempic (semaglutide 0.5 mg and 1.0 mg) has become one of the most talked-about medications in recent years, primarily due to its dramatic weight loss effects — even though it is technically licensed only for type 2 diabetes in the UK, not for weight management.

There are several reasons why people look for alternatives:

• •Supply shortages: Ozempic has experienced ongoing supply constraints globally, driven by off-label use for weight loss that has outstripped manufacturing capacity. While supply has improved in 2026, intermittent shortages continue to affect some pharmacies.
• •Cost: On private prescription, Ozempic costs approximately £200–300 per month. For many people, this is prohibitively expensive for long-term use.
• •NHS restrictions: Ozempic is prescribed on the NHS for type 2 diabetes, not for weight loss. If your GP prescribes it for diabetes, NHS prescription charges apply (£9.90 in England, free in Scotland/Wales/NI), but obtaining it purely for weight management through the NHS is generally not possible.
• •Side effects: Some patients experience intolerable nausea, vomiting, or other gastrointestinal side effects on semaglutide and may tolerate a different medication better.
• •Seeking greater efficacy: Some patients want more potent weight loss than semaglutide provides and are interested in newer options like tirzepatide.

It is crucial to understand that Ozempic is a prescription-only medicine (POM) regulated by the MHRA. Any alternative should also be obtained through legitimate medical channels — not purchased from unregulated online sources.

The most direct "alternative" to Ozempic for weight loss is actually the same active ingredient — semaglutide — but in a formulation specifically licensed for weight management.

Key differences from Ozempic: - Higher dose: Wegovy's maintenance dose is 2.4 mg weekly, compared to Ozempic's maximum of 2.0 mg (most commonly prescribed at 0.5 mg or 1.0 mg for diabetes) - Licensed indication: Wegovy is MHRA-approved and NICE-recommended specifically for weight management - Dose escalation: Wegovy has a structured 16-week dose escalation protocol designed specifically for weight management patients

Why choose Wegovy over Ozempic for weight loss: - Using a medication for its licensed indication means you receive the tested and approved dose for that purpose - NICE Technology Appraisal means it is available through the NHS (via specialist weight management services) for eligible patients - Clinical trial data (the STEP programme) specifically demonstrated safety and efficacy for weight management

Availability and cost: Wegovy supply in the UK has improved through 2025–2026, though some pharmacies still experience intermittent stock issues. Private costs are approximately £200–300 per month at maintenance dose — broadly comparable to Ozempic.

Bottom line: If you are using or considering Ozempic specifically for weight loss rather than diabetes, Wegovy is the medically appropriate choice. It is the same molecule, at the dose proven in clinical trials for weight management, with a proper regulatory pathway.

Mounjaro (tirzepatide) is arguably the most compelling alternative to Ozempic for those seeking maximum weight loss. It represents a genuinely different mechanism of action — not just another GLP-1 agonist, but a dual GIP/GLP-1 receptor agonist.

Head-to-head comparison with semaglutide: In the SURMOUNT-5 trial, which directly compared tirzepatide 15 mg against semaglutide 2.4 mg, tirzepatide produced significantly greater weight loss — approximately 20.2% versus 13.7% over 72 weeks. This is the most rigorous head-to-head evidence available.

Advantages over Ozempic/semaglutide: - Greater average weight loss in clinical trials - Dual mechanism of action may provide additional metabolic benefits - Some patients who do not respond well to semaglutide may respond to tirzepatide - Comparable or potentially better tolerability in some studies

Considerations: - Mounjaro is a newer medication with less long-term safety data than semaglutide - Individual response varies — some patients may still do better on semaglutide - Switching between GLP-1 medications should be managed by a prescriber, with appropriate washout or transition protocols

UK availability: Mounjaro is available both through NHS pathways (for diabetes and, increasingly, for weight management via NICE appraisal) and through private clinics. Private costs range from approximately £150–280 per month depending on dose level.

Who might prefer Mounjaro: - Patients who have reached a weight loss plateau on semaglutide - Those seeking the highest possible weight loss - Patients who experience significant side effects on semaglutide and want to try a different receptor profile

Saxenda (liraglutide 3.0 mg) is the oldest of the currently available weight loss injections in the UK and, while less potent than semaglutide or tirzepatide, remains a viable alternative for certain patients.

When Saxenda makes sense as an Ozempic alternative: - Tolerability: Some patients experience fewer GI side effects on liraglutide than on semaglutide. If nausea or vomiting has been a significant problem with Ozempic, Saxenda may be better tolerated. - Availability: Saxenda has had fewer supply issues than Wegovy or Ozempic, as demand has shifted towards the newer weekly injectables. - Preference for daily dosing: While most patients prefer weekly injections, some prefer the daily routine, finding it easier to remember and offering the flexibility to skip a dose if needed without waiting a full week.

Clinical performance: - Average weight loss of approximately 8% of body weight over 56 weeks (compared to ~15% with semaglutide 2.4 mg) - Clinically meaningful improvements in blood pressure, blood lipids, and glycaemic control - Longer safety track record than newer alternatives

Cost: Approximately £180–250 per month privately — comparable to the newer options.

NICE guidance: Saxenda's NICE recommendation (TA664) has somewhat more restrictive criteria than Wegovy, generally requiring a BMI of 35+ (or 32.5+ for certain ethnic groups) with pre-diabetes. This means NHS access may be more limited.

Realistic expectations: Saxenda will not produce the dramatic 15–20%+ weight loss seen with semaglutide or tirzepatide. However, an 8% weight loss from a starting weight of, say, 100 kg is still 8 kg — which is clinically meaningful and can significantly improve metabolic health markers.

For patients who have a strong aversion to injections, oral semaglutide — marketed as Rybelsus — offers an alternative route of administration for the same active ingredient found in Ozempic and Wegovy.

Important context: Rybelsus is currently MHRA-approved in the UK for type 2 diabetes only, not for weight management. However, it demonstrates the feasibility of oral GLP-1 therapy, and higher-dose oral semaglutide formulations for weight management are in development.

How oral semaglutide works: Rybelsus tablets contain semaglutide combined with an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), which protects the peptide from stomach acid and facilitates absorption through the gastric lining. The tablet must be taken on an empty stomach with no more than 120 ml of water, and the patient must wait at least 30 minutes before eating, drinking, or taking other medications.

Dosing: Available in 3 mg, 7 mg, and 14 mg tablets, taken once daily. The 14 mg oral dose produces plasma semaglutide levels roughly equivalent to the 0.5 mg injectable dose — significantly lower than the 2.4 mg weekly dose used in Wegovy for weight management.

Limitations as a weight loss alternative: - The currently available oral doses produce less weight loss than injectable semaglutide at weight-management doses - Strict fasting requirements can be inconvenient - Bioavailability is only approximately 1% — meaning 99% of the ingested semaglutide is not absorbed - Not licensed for weight management in the UK

Future developments: Novo Nordisk is developing higher-dose oral semaglutide formulations (up to 50 mg) specifically for weight management, with improved bioavailability. Early clinical data suggests these may eventually approach the efficacy of injectable semaglutide, which could transform the treatment landscape by removing the need for injections entirely.

Cost: On private prescription for diabetes, Rybelsus costs approximately £70–100 per month — less than the injectable options, though this reflects the lower effective dose rather than a cost advantage per unit of efficacy.

The weight loss medication pipeline is exceptionally active, with several next-generation compounds showing promise in clinical trials. While none of these are currently available in the UK, they represent the future landscape of alternatives.

Retatrutide (Eli Lilly): A triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trial results published in 2023 showed remarkable weight loss of up to 24% over 48 weeks — even exceeding tirzepatide. Phase 3 trials are underway, and if successful, MHRA approval could follow within 2–3 years. The addition of glucagon receptor agonism may enhance fat metabolism and energy expenditure beyond what current dual agonists achieve.

Survodutide (Boehringer Ingelheim): A dual GLP-1/glucagon receptor agonist showing approximately 18–19% weight loss in Phase 2 trials over 46 weeks. Survodutide is also being investigated for its potential to treat metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), which could make it particularly valuable for patients with both obesity and liver disease.

Orforglipron (Eli Lilly): A non-peptide oral GLP-1 agonist — unlike oral semaglutide, orforglipron is a small molecule rather than a peptide, meaning it does not require the special absorption-enhancing technology. Phase 2 data showed approximately 14.7% weight loss over 36 weeks with better oral bioavailability than Rybelsus and without the strict fasting requirements. This could be a game-changer for oral weight loss therapy.

Amycretin (Novo Nordisk): A dual amylin/GLP-1 agonist in early clinical development. Preliminary data suggests weight loss comparable to tirzepatide, with a different mechanism (amylin receptor agonism promotes satiety through a distinct neural pathway). Both injectable and oral formulations are being developed.

CagriSema (Novo Nordisk): A fixed-dose combination of cagrilintide (an amylin analogue) and semaglutide in a single weekly injection. Phase 3 trial results (the REDEFINE programme) show approximately 22–24% weight loss — competing directly with tirzepatide for best-in-class efficacy.

Timeline for UK availability: These compounds are at varying stages of clinical development. The earliest any might receive MHRA approval is likely 2027–2028, with others potentially arriving in 2029–2030. Regulatory timelines can shift based on trial results and MHRA review processes.

It is important to address the distinction between licensed pharmaceutical medications and research-grade compounds when discussing Ozempic alternatives, as confusion between the two categories creates significant safety risks.

Pharmaceutical (licensed) alternatives: - Manufactured to Good Manufacturing Practice (GMP) standards - Subject to rigorous clinical trials demonstrating safety and efficacy - Approved by the MHRA with ongoing pharmacovigilance monitoring - Prescribed by registered healthcare professionals - Dispensed by regulated pharmacies - Examples: Wegovy, Mounjaro, Saxenda, Rybelsus

Research-grade compounds: - Sold as "for research purposes only" and not for human consumption - No GMP manufacturing requirement (though some suppliers voluntarily adhere to high standards) - No regulatory approval for human use - Variable purity and potency — even with a certificate of analysis (CoA), there is no regulatory oversight of manufacturing - Examples: research-grade semaglutide, BPC-157, various peptide compounds from online suppliers

The critical distinction: Some people, frustrated by the cost or availability of prescription weight loss medications, turn to research-grade semaglutide or tirzepatide purchased from peptide suppliers. This carries significant risks:

• •Purity concerns: Without pharmaceutical-grade manufacturing, contaminants (endotoxins, incorrect peptide sequences, degradation products) may be present
• •Dosing uncertainty: Research compounds may not contain the stated amount of active ingredient, making accurate dosing difficult
• •Legal grey area: While purchasing research peptides is not itself illegal in the UK, self-administering them is legally and medically problematic
• •No medical oversight: Without a prescriber monitoring your treatment, adverse effects and drug interactions may go undetected

The recommended approach: If cost is a barrier, explore NHS pathways (which may provide these medications at standard prescription charges), discuss lower-cost alternatives with your GP or a private prescriber, and investigate patient assistance programmes. The safety profile of pharmaceutical-grade medications is well-established — the same cannot be said for unregulated research compounds.

This article is for educational purposes only and does not constitute medical advice. Always consult a registered healthcare professional before starting any weight loss medication.